News & Perspective

Nov 01, 2007

Nov 01, 2007

THE PANDEMIC VACCINE PUZZLE Part 6: Looking to novel vaccine technologies

Editor's note: This is the sixth in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Dec 18, 2007

Dec 18, 2007

Funding cuts said to threaten states' preparedness progress

(CIDRAP News) – Several states have made progress preparing for a major public health emergency such as a pandemic or bioterror attack, but funding shortfalls at the federal level threaten to stall or even reverse recent gains, according to a report today from the nonprofit organization Trust for America's Health (TFAH).

Mar 10, 2008

Mar 10, 2008

Hectic season exposes gaps in flu preparedness

(CIDRAP News) – Friday's announcement by the Centers for Disease Control and Prevention (CDC) that influenza appears to be slowing down has left medical personnel relieved for the imminent end of a harsh flu season.

But it has also left them worried over weaknesses that the season exposed in public health's ability to anticipate flu's behavior, and over doubts raised among their patients by the flu vaccine's diminished effectiveness.

Apr 03, 2008

Apr 03, 2008

China approves its first H5N1 vaccine

(CIDRAP News) – China's State Food and Drug Administration (SFDA) yesterday approved the country's first prepandemic H5N1 influenza vaccine, an inactivated whole-virus product made by Sinovac, a Beijing-based biotechnology company.

Apr 25, 2008

Apr 25, 2008

IOM: US likely to need bigger antiviral stockpile

(CIDRAP News) – The US government will need to expand its stockpile of antiviral drugs if the goal is to have enough doses to treat all patients and provide preventive treatment for some others at risk in an influenza pandemic, the Institute of Medicine (IOM) says in a report issued today.

Apr 29, 2008

Apr 29, 2008

HHS adds H5N1 clade 2.2 vaccine to stockpile

(CIDRAP News) – The US Department of Health and Human Services (HHS) has accepted the first batch of H5N1 avian influenza vaccine based on the H5N1 variant known as clade 2.2, which has spread most widely across Asia, Europe, and Africa.

May 19, 2008

May 19, 2008

EU approves its first prepandemic H5N1 vaccine

(CIDRAP News) – An H5N1 influenza vaccine made by the British pharmaceutical company GlaxoSmithKline (GSK) has become the first prepandemic vaccine to be licensed by the European Union (EU), the company announced today.

Jun 03, 2008

Jun 03, 2008

HHS offers pandemic guidance on masks, antivirals

(CIDRAP News) – Proposed pandemic preparedness guidance released by the federal government today recommends that people wear face masks if they have to go into crowds during an influenza pandemic and says critical infrastructure businesses should consider stockpiling antiviral drugs, among various other suggestions.

Jun 16, 2008

Jun 16, 2008

Sanofi to give WHO 60 million doses of H5N1 vaccine

(CIDRAP News) – Sanofi Pasteur pledged today to give 60 million doses of H5N1 influenza vaccine over 3 years to the World Health Organization (WHO) for a planned stockpile to help poor countries in the event of an influenza pandemic.

Pages

by Topic

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»